Related Experiment Video

Updated: Jun 28, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

The UPS: a promising target for breast cancer treatment

Ko Sato1, Eeson Rajendra, Tomohiko Ohta

  • 1Division of Breast and Endocrine Surgery, St Marianna University School of Medicine, Kawasaki, 216-8511, Japan.

BMC Biochemistry
|November 26, 2008
PubMed

Insights

Triple-negative breast cancer (TNBC) survival is poor, but targeting the ubiquitin proteasome system offers new therapeutic hope. Research explores ubiquitin E3 ligases in ESR1, ERBB2, and BRCA1 pathways for novel breast cancer drug development.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Advances in endocrine therapy and trastuzumab have reduced mortality for hormone receptor-positive and ERBB2-positive breast cancers.
  • Triple-negative breast cancer (TNBC), lacking estrogen receptor (ESR1), progesterone receptor (PRGR), and ERBB2 (HER2) expression, presents a significant therapeutic challenge with poor prognosis.
  • TNBC shares phenotypic similarities with basal-like breast cancer, often linked to BRCA1 pathway deficiencies.

Purpose of the Study:

  • To review the role of ubiquitin proteasome pathways in breast cancer, particularly in relation to ESR1, ERBB2, and BRCA1.
  • To discuss the potential of targeting the ubiquitin proteasome system (UPS) for novel breast cancer therapeutics.
  • To explore the therapeutic implications of ubiquitin E3 ligases in breast cancer treatment.

Main Methods:

  • Literature review of ubiquitin proteasome pathways and their relevance to breast cancer.
  • Analysis of DNA microarray data linking TNBC to basal-like breast cancer and BRCA1 pathways.
  • Examination of existing therapeutic strategies and emerging drug targets in breast cancer.

Main Results:

  • The ubiquitin proteasome system (UPS) is increasingly recognized as a potential therapeutic target in oncology.
  • Bortezomib's success in multiple myeloma suggests proteasome inhibitors could be effective against other cancers, including breast cancer.
  • Specific ubiquitin E3 ligases involved in ESR1, ERBB2, or BRCA1 pathways represent promising targets for drug development.

Conclusions:

  • Targeting the ubiquitin proteasome system offers a promising avenue for developing new treatments for triple-negative breast cancer.
  • Further research into ubiquitin E3 ligases associated with key breast cancer pathways could lead to innovative therapeutic interventions.
  • Developing novel drugs targeting the UPS may significantly improve survival rates for patients with aggressive forms of breast cancer.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Upstream Processing01:27

Upstream Processing

Upstream processing represents a critical phase in biomanufacturing, wherein biological systems such as microorganisms, mammalian cells, or insect cells are cultivated to produce therapeutic proteins, vaccines, enzymes, or other biologically derived products. This phase encompasses all steps from the selection and genetic manipulation of the production organism to the cultivation of cells in bioreactors under tightly controlled environmental conditions.Host Selection and Genetic OptimizationThe...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...